Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M; East Japan Chesters Group.
Tozuka T, et al. Among authors: yamaguchi t.
Lung Cancer. 2024 Mar 24;191:107540. doi: 10.1016/j.lungcan.2024.107540. Online ahead of print.
Lung Cancer. 2024.
PMID: 38614069